Sheldon L. Koenig serves as the President and Chief Executive Officer of Esperion Therapeutics Inc., a pharmaceutical company focused on developing and commercializing innovative therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With over 25 years of experience in the biopharmaceutical industry, Koenig has a proven track record of leadership and success in bringing novel therapies to market. Prior to joining Esperion in 2016, he held executive positions at several prominent companies, including Amgen, where he served as Vice President and General Manager of the Bone Health Business Unit, and Genzyme, where he was Senior Vice President and General Manager of the Cardiovascular Business Unit. Under Koenig's leadership, Esperion has made significant strides in advancing its mission to reduce the risk of cardiovascular disease through the development of its lead product, Nexletol (bempedoic acid), and its combination therapy, Nexlizet (bempedoic acid and ezetimibe). These oral, once-daily treatments have been approved by the FDA for use in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering. Koenig's strategic vision and dedication to improving patient outcomes have been instrumental in securing partnerships with leading pharmaceutical companies and expanding Esperion's global presence. As CEO, Koenig is responsible for overseeing all aspects of Esperion's operations, from research and development to commercialization and investor relations. His leadership style emphasizes collaboration, innovation, and a patient-centric approach. Koenig's extensive experience in the industry, coupled with his passion for advancing cardiovascular health, has positioned Esperion as a key player in the fight against the global burden of high cholesterol and related diseases.